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PURPOSE: Data are conflicting concerning the risk for ischemic stroke associated with a common polymorphism in the gene
encoding 5,10-methylenetetrahydrofolate reductase C677T, which predisposes carriers to hyperhomocysteinemia. A meta-analysis
study suggested that the 5,10-methylenetetrahydrofolate reductase 677TT genotype might have a small influence in determining
susceptibility to ischemic stroke.
METHODS: We analyzed the 5,10-methylenetetrahydrofolate reductase 677TT genotype polymorphism in Brazilian subjects
with ischemic stroke, using a case-control design.
RESULTS: We compared 5,10-methylenetetrahydrofolate reductase genotypes in groups of subjects presenting ischemic stroke
(n = 127) and normal control (n = 126) and found an odds ratio of 1.97 (95% CI, 0.84-4.64) in a multivariate analysis in which
results were adjusted to baseline clinical characteristics of study participants.
CONCLUSION: We found that the homozygous 5,10-methylenetetrahydrofolate reductase C677T genotype was not a risk
factor for ischemic stroke in these Brazilian subjects.
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INTRODUCTION
Ischemic stroke, which results from the abrupt interrup-
tion of focal cerebral blood flow1,2 for more than 24 hours,
plays an important role in death and disability worldwide. It
is the third leading cause of death and the leading cause of
serious long-term disability in the United States. Approxi-
mately 750,000 strokes occur annually, with a mortality rate
exceeding 150,0003–6 in a year.
Because stroke is a complex disease comprising a het-
erogeneous group of disorders with multiple risk factors,
research into the genetics of stroke presents unique chal-
lenges. Among many genetic factors that have been stud-
ied in this context, the common polymorphism in the gene
encoding 5,10-methylenetetrahydrofolate reductase
(MTHFR C677T) may be of importance. The enzyme
MTHFR catalyzes the reduction of 5,10-methylene-
tetrahydrofolate to 5-methyltetrahydrofolate, the predomi-
nant circulating form of folate and carbon donor for the
remethylation of homocysteine to methionine and plays a
crucial role in regulating the levels of homocyteine. This
thermolabile variant form of MTHFR appears to facilitate
the manifestation of hyperhomocysteinemia, which in-
creases the risk of vascular disease and stroke7–14 up to 2.5-
fold, according to a meta-analysis study.10
However, other studies fail to demonstrate any association
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between ischemic stroke and the MTHFR 677TT genotype.15,16
According to Markus et al,16 the homozygous thermolabile
genotype was not associated with ischemic cerebrovascular
disease, despite the significant association of the genotype with
elevated homocysteine in the patient group. Kelly et al17, in
another meta-analysis study demonstrated the association be-
tween mild-to-moderate hyperhomocysteinemia and ischemic
stroke, and more recently this polymorphism has been sug-
gested as a genetic risk factor for ischemic stroke.18 In con-
trast, other authors have reported that the MTHFR 677TT
genotype may have a small influence in determining suscep-
tibility to ischemic stroke.16
In the present work, we investigated the prevalence of
MTHFR genotypes in Brazilian patients with ischemic stroke,
to assess likehood they represent a risk factor for this disease.
SUBJECTS AND METHODS
Study population
Stroke was defined as an episode of sudden-onset
lateralized neurological deficit and was confirmed by objec-
tive evidence of ischemia on computed tomography brain
scan. After approval by the Research Ethics Committee of
Hospital das Clínicas, São Paulo University Medical School,
informed consent was obtained from 127 patients with stroke
in the period of 1999 to 2004. The following information
regarding known risk factors for stroke was obtained from
each patient (through patient/caregiver interview, patients’
medical records, and laboratory tests and clinical exams):
hypertension, current smoking, history of previous stroke,
cardiovascular disorders (ischemic heart disease, atrial fibril-
lation, and congestive cardiac failure), diabetes mellitus,
dyslipidemia, and chronic renal insufficiency. Control sub-
jects (n = 126) were recruited from the same hospital. The
exclusion criteria for control subjects were a past history of
symptomatic stroke. Neuroimaging was not performed for
control patients, so that it is possible that controls with si-
lent lesions could have been included. Patients with cerebral
hemorrhage, transient ischemic attack, or cerebral venous
thrombosis were not included in the present work.
MTHFR C677T genotyping
DNA was extracted from peripheral venous blood collected
with EDTA by a salting out method.19 Polymerase chain re-
action (PCR) amplification of the DNA samples was peformed
following the method described by Frosst et al.11 Restriction
analysis with the enzyme HinfI (Boehringer Mannheim, Ger-
many) was performed according to the manufacturer’s recom-
mendation. Digestion fragments were separated by 8%
polyacrilamyde gel electrophoresis and visualized under ul-
traviolet light following ethidium bromide staining.
Statistical analysis
Differences among the genotype groups were examined
with the use of Pearson’s χ2 test or the unpaired Student t
test when appropriate. Significance was considered when
P < 0.05. The 95% confidence intervals (95% CI) of the
percentage were calculated by assuming a normal distri-
bution. Goodness-of-fit of genotype distribution to Hardy-
Weinberg equilibrium was examined. All calculations were
performed using the computer program STATA version 7.0
(STATA Corp., College Station, TX, USA).
RESULTS
Demographic characteristics of the subjects partici-
pating in the study are shown in Table 1. Mean age was
Table 1 - Clinical and demographic characteristics of ischemic stroke patients and control subjects studied
Case Control p value
Average age, year 64.0 63.5 1.000
Male (%) 53 (41.7) 72 (57.2) 0.028
Ethnic origin
White (%) 82 (64.6) 85 (67.5)
Black (%) 32 (25.2) 31 (24.6) 0.060
Yellow (%) 13 (10.2) 10 (7.9)
Hypertension (%) 53 (41.7) 28 (22.2) 0.000
Current smoking (%) 22 (17.3) 9 (7.1) 0.069
Atrial fibrillation (%) 12 (9.5) 2 (1.6) 0.078
Ischemic heart disease (%) 9 (7.1) 2 (1.6) 0.830
Dislipidemic (%) 50 (39.4) 52 (41.3) 0.758
Congestive cardiac failure (%) 6 (4.7) 1 (0.8) 0.057
Diabetes mellitus (%) 18 (14.2) 16 (12.7) 0.731
Chronic renal insufficiency (%) 6 (4.7) 3 (2.4) 0.341
Total (%) 127 (100) 126 (100)
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63.8 years (range, 16-93 years). The case and control
groups are similar, except for statistically significant pre-
dominance of men in the control group and hyperten-
sion in the case group, supporting the latter as a risk fac-
tor for stroke.
The distribution of MTHFR genotypes in the case and
control groups is shown in Table 2. The frequencies of
MTFHR genotypes were calculated, and the Hardy-
Weinberg equilibrium test for MTHFR 677TT showed no
significant discrepancy in the genotype distribution of the
allele frequency (χ2=0.15, p = 0.70). The allele distribu-
tion was 0.65 for control and 0.35 for case groups. The
prevalence of the homozygous thermolabile MTHFR
677TT genotype was higher in the ischemic stroke group
(observed in 20 cases - 15.7%) than in the age-matched
controls (present in only 12 control subjects (9.5%). How-
ever, the distribution of these values showed Pearson’s
χ2=2.5767 and p = 0.276, meaning that the observed trend
is not significant for the number of subjects included in
the study (OR, 1.97; 95%CI, 0.84-4.64 for MTHFR 677TT
and OR, 0.84; 95%CI, 0.49-1.43 for MTFHR C677T, com-
pared to MTHFR 677CC as the reference).
DISCUSSION
Reported data concerning risk for ischemic stroke as-
sociated with the common polymorphism C677T in the
gene encoding MTHFR are thus far conflicting.
In the present case-control study, we investigated the
relationships between MTHFR C677T polymorphism and
other variables well known to be associated with an
atherosclerotic risk in a Brazilian population.
We have shown that the homozygous MTHFR 677TT
genotype is not a risk factor for ischemic stroke in these
Brazilian subjects. In a meta-analysis study, Kelly et al17
analyzed 19 published works (2788 stroke and 3962
nonstroke cases) on MTHFR polymorphism and con-
cluded that the MTHFR 677TT genotype can be consid-
ered a mild-to-moderate risk factor for ischemic stroke.
These authors found a small influence (pooled OR, 1.23;
95% CI, 0.96-1.58) of the MTHFR 677TT genotype on
stroke risk, which showed a trend toward disease, but did
not reach the threshold for statistical significance. In a
subsequent meta-analysis study, Cronin et al18 showed a
gradual increase in ischemic stroke risk with increasing
MTHFR 677T allele (OR, 1.48; 95% CI, 1.22-1.80), sug-
gesting an influence of this polymorphism as a genetic
stroke risk factor.
The association between the genotype and homocys-
teinemia is dependent, at least in part, on serum folate
levels. Harmon et al13 and Jacques et al20 found that el-
evated homocysteine was only associated with the
genotype in individuals with folate levels below the
population median. Therefore, the activity of the ther-
molabile variant of this enzyme must be influenced by
the availability of folate. Individuals who are ho-
mozygous for the thermolabile variant of MTHFR and
who have low plasma folate levels may be particularly
prone to moderate/intermediate homocysteinemia. Ac-
cording to Guttormsen et al,21 plasma homocysteine lev-
els in such individuals can be lowered by using folic
acid. In the present study, the folate and homocysteine
status of the population has not been determined.
Frequencies of the thermolabile MTFHR genotype
vary dramatically depending on different ethnic back-
ground, from 025 to 16.7%26. For white populations in
US and Australia, the frequency is about 11.5%27. In Bra-
zil, this genotype frequency is 14.9% and 11.8% in white
individuals with stroke and without stroke, respectively;
in black individuals, these frequencies are lower, being
10.3% and 1.9% in patients with stroke and without
stroke, respectively28. According to Carod-Artal et al,29
the thermolabile MTFHR genotype occurred in 5.05%
and 10% of elderly and young individuals with stroke,
respectively, admitted to a rehabilitation hospital. On the
other hand, it has been shown that the frequency of this
genotype is higher in Italy,30 but paradoxically, cardio-
vascular complications are estimated to be relatively low.
Different dietary habits could explain this paradox,
where the typical Mediterranean diet comprises foods
with high content of folate, such as green vegetables and
orange juice. Another hypothesis could be a possible pro-
tective role of the thermolabile MTHFR variant in the
presence of other genetic disorders, which are particu-
larly prevalent in littoral people of Mediterranean re-
gion.31 In the present work, we found prevalence of the
thermolabile MTHFR variant in 15.7% in the case group
compared with 9.5% in the control group. Therefore, in
general, the prevalence of the thermolabile MTHFR vari-
ant in these Brazilian subjects was much higher than that
described in the literature.
Table 2 - Distribution of 5,10-methylenetetrahydrofolate
reductase genotypes in ischemic stroke cases and control
group
MTHFR genotype Control group Ischemic stroke
TT (%) 12 (9.5) 20 (15.7)
CT (%) 60 (47.6) 52 (41.0)
CC (%) 54 (42.8) 55 (43.3)
Total (%) 126 (100) 127 (100)
Pearson χ2=2.5767 p=0.276; MTHFR: 5,10-methylenetetrahydrofolate
reductase
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In summary, we have shown that the homozygous
MTHFR 677TT genotype does not appear to be a risk
factor for ischemic stroke in Brazilians. Although the
present result is not statistically powerful because of the
small number of subjects included, it should be consid-
ered as a relevant preliminary data collection program,
leading to further future studies, including dietary infor-
mation, such as folate intake and serum measurements
of homocysteine and folate levels, to better evaluate the
possible risk factors involved in stroke. Further studies
are necessary with larger case-control samples that are
better matched for gender to confirm our results.
RESUMO
Nagahashi Marie SK, Shinjo SK, Oba-Shinjo SM, da Silva
R, Barbosa KC, Yamamoto F, Scaff M. Polimorfismo no
gene de metilenetetrahidrofolato redutase não está
relacionado com o risco de doença cerebrovascular
isquêmica em uma população brasileira. Clinics.
2007;62(3):295-300.
OBJETIVO. Os dados são conflitantes em relação a risco
de acidente cerebrovascular associado a polimorfismo do
gene 5,10-metilenetetrahidrofolato redutase C677T, o qual
predispõe a hiperhomocisteinemia. Um estudo de meta-
análise sugere que o genotipo 5,10-metilenetetrahidrofolato
redutase 677TT poderia ter uma pequena influência em
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determinar susceptibilidade a acidente cerebrovascular.
MÉTODOS: Analisamos este polimorfismo em indivíduos
brasileiros com acidente cerebrovascular isquêmico,
baseando-se em um estudo de caso-controle.
RESULTADOS: Comparamos os genótipos 5,10-
metilenetetrahidrofolato redutase em grupos de indivíduos
com acidente cerebrovascular isquêmico (n=127) e controle
normal (n=126), e encontramos Odds Ratio de 1,97 (IC 95%
0,84 - 4,64) em uma análise multivariada, na qual os
resultados foram ajustados a características clínicas basais
dos indivíduos estudados.
DISCUSSÃO: Nossos estudos indicam que o genótipo 5,10-
metilenetetrahidrofolato redutase C677T não é um fator de
risco para acidente cerebrovascular isquêmico entre
indivíduos brasileiros.
UNITERMOS: Genótipo, Homocisteína, Acidente cere-
brovascular isquêmico, Polimorfismo, Fator de risco.
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